Increased regulatory scrutiny on psychedelic biotech companies.
Biogen and Eli Lilly are actively pursuing acquisitions.
Doctors Without Borders raises concerns about Gilead's practices.
Strategic angle: Biogen and Eli Lilly make takeover moves, while Doctors Without Borders criticizes Gilead amidst growing concerns in the biotech sector.
Increased regulatory scrutiny on psychedelic biotech companies.
Biogen and Eli Lilly are actively pursuing acquisitions.
Doctors Without Borders raises concerns about Gilead's practices.